The latest leukaemia news
ASH 2022: New results from the phase 3 GLOW study of fixed-duration treatment with ibrutinib plus venetoclax demonstrate robust efficacy and sustained response in older, unfit patients with previously untreated chronic lymphocytic leukaemia
New four-year follow-up results from the Phase 3 GLOW study (Abstract #93), were announced during…